Allogene Therapeutics, Inc. ALLO R2KR3KPHARMA
Company Overview
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.29.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +89.42% |
| 6 Months: | -14.35% |
| 3 Months: | +4.79% |
| 1 Month: | +0.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.05 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 35.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALLO Allogene Therapeutics, Inc. R2KR3KPHARMA | 1.97 | -2.56 | $679.95M | 0.00% | -53.97% | -52.32% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 38.34M | 44.00K | 49.00K | 39.00K | 64.00K | 27.00K | 30.00K | 22.00K | 22.00K | 22.00K | 0 | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 65.19M | 54.44M | 44.90M | 42.40M | 46.09M |
| Operating Income | -2.60M | -135.01M | -22.19M | -33.05M | -36.46M | -45.96M | -55.01M | -64.58M | -57.68M | -63.16M | -68.04M | -33.20M | -71.03M | -77.67M | -80.01M | -76.62M | -82.51M | -99.09M | -80.54M | -63.00M | -69.50M | -71.43M | - | - | -65.19M | -54.44M | -44.90M | -42.40M | -46.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -56.48M | -47.57M | -37.96M | -35.44M | -39.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 150.00K | 268.00K | 344.00K | 313.00K | 300.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -59.73M | -50.94M | -41.40M | -38.81M | -42.61M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.60M | -134.90M | -43.50M | -30.51M | -31.59M | -41.24M | -50.73M | -61.03M | -54.48M | -60.97M | -66.20M | -33.02M | -70.94M | -78.19M | -78.61M | -80.29M | -84.24M | -99.97M | -79.23M | -62.29M | -65.00M | -66.36M | - | - | -59.73M | -50.94M | -41.40M | -38.81M | -42.61M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.53 | -0.52 | -0.25 | -0.53 | -0.57 | -0.56 | -0.56 | -0.59 | -0.69 | -0.54 | -0.37 | -0.38 | -0.35 | - | - | -0.28 | -0.23 | -0.19 | -0.17 | -0.18 |
| R&D Expense | - | 122.49M | 10.87M | - | 23.40M | 31.77M | 39.99M | - | 42.04M | 47.30M | 51.42M | 55.18M | 52.29M | 58.72M | 60.16M | 57.17M | 63.64M | 80.24M | 62.04M | 45.98M | 52.26M | 50.35M | 44.71M | - | 50.20M | 40.16M | 31.16M | - | 32.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | - | 156.00K | 95.00K | 22.00K | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 335.69M | 314.59M | 257.50M | 206.93M |
| Operating Income | -192.84M | -202.01M | -258.24M | - | -335.54M | -314.49M | -257.48M | -206.93M |
| EBITDA | - | - | - | - | -321.24M | -313.07M | -243.33M | -177.45M |
| Interest Expense | - | - | - | - | - | 0 | 181.00K | 1.07M |
| Pretax Income | - | - | - | - | -340.41M | -327.26M | -257.15M | -190.89M |
| Tax Provision | - | - | - | 0 | - | 0 | 443.00K | 0 |
| Net Income | -211.50M | -184.59M | -250.22M | - | -340.41M | -327.26M | -257.59M | -190.89M |
| Diluted EPS | - | -1.83 | -2.08 | - | -2.32 | -2.09 | -1.32 | -0.87 |
| R&D Expense | 151.86M | 144.53M | 192.99M | 220.18M | 256.39M | 242.91M | 192.30M | 150.15M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Nov 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 773.86M | 717.80M | 1.23B | - | 978.09M | 955.62M | 894.48M | 821.58M | 750.13M | 773.01M | 713.41M | 642.84M | 548.71M | 415.90M |
| Current Assets | - | - | - | - | - | - | - | - | - | 528.82M | - | - | - | 459.12M | 303.39M | 257.75M |
| Cash & Equivalents | - | - | 92.43M | 175.13M | 183.35M | - | 84.51M | 96.04M | 74.36M | 61.90M | 109.93M | 154.76M | 69.25M | 83.16M | 75.22M | 51.69M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.00K | 70.69M | 88.78M | 148.21M | - | 112.82M | 149.14M | 151.08M | 154.70M | 158.12M | 151.60M | 132.78M | 130.60M | 126.53M | 123.36M |
| Current Liabilities | - | 2.00K | 29.46M | 33.08M | 94.32M | - | 36.62M | 44.18M | 48.08M | 53.73M | 59.40M | 54.58M | 37.49M | 37.08M | 35.52M | 32.51M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 101.12M | - | - | - | 95.12M | 90.76M | 83.25M |
| Total Equity | 0 | -2.00K | 703.16M | 629.02M | 1.01B | - | 865.27M | 806.48M | 743.40M | 666.88M | 592.01M | 621.41M | 580.63M | 512.23M | 422.18M | 292.54M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 144.44M | - | - | - | 168.64M | 212.21M | 229.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -44.65M | -137.35M | -115.09M | - | -220.52M | -237.73M | -200.30M | -149.25M |
| Investing Cash Flow | -632.80M | 164.08M | -505.12M | - | 106.16M | 163.29M | 75.69M | 95.56M |
| Financing Cash Flow | 771.18M | 58.96M | 633.59M | - | 2.95M | 95.69M | 116.67M | 30.16M |
| Capital Expenditure | -3.23M | -50.79M | -65.96M | - | -5.19M | -1.52M | -694.00K | -386.00K |
| Free Cash Flow | -47.89M | -188.14M | -181.05M | - | -225.71M | -239.25M | -200.99M | -149.63M |
| Net Change in Cash | - | - | - | - | -111.41M | 21.25M | -7.94M | -23.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -215,087.2% | -331,044.2% | -1,170,372.7% | - |
| Net Margin % | - | - | - | - | -218,214.1% | -344,489.5% | -1,170,863.6% | - |
| ROE % | -30.1% | -29.3% | -24.7% | - | -51.0% | -63.9% | -61.0% | -65.3% |
| ROCE % | -25.9% | -29.5% | -22.8% | - | -43.7% | -51.9% | -50.2% | -54.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.73% | 30.15M | $60.90M |
| 2 | Frazier Life Sciences Management, L.P. | 6.50% | 22.45M | $45.34M |
| 3 | Pfizer Inc | 6.38% | 22.03M | $44.50M |
| 4 | State Street Corporation | 5.51% | 19.03M | $38.43M |
| 5 | TPG GP A, LLC | 5.42% | 18.72M | $37.81M |
| 6 | Sio Capital Management, LLC | 3.86% | 13.32M | $26.91M |
| 7 | Primecap Management Company | 3.80% | 13.12M | $26.51M |
| 8 | Vanguard Capital Management LLC | 3.52% | 12.17M | $24.58M |
| 9 | FMR, LLC | 3.48% | 12.01M | $24.26M |
| 10 | Citadel Advisors Llc | 2.92% | 10.09M | $20.38M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALLO
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune…
Allogene Therapeutics Announces Participation in September Investor Conference
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune …
Allogene (ALLO) Q2 2026 Earnings Call Transcript
Cema-cel hit 58.3% MRD negativity in ALPHA3 with zero treatment hospitalizations.
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says
Allogene Therapeutics (ALLO) remains attractive given its undemanding valuation and differentiated c
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ...
Allogene Therapeutics Inc (ALLO) advances its allogeneic CAR-T pipeline with key regulatory milestones and strong trial momentum, while navigating solid tumor challenges and competitive pressures.
ALLO — Frequently Asked Questions
What is the current share price of Allogene Therapeutics, Inc. (ALLO)?
As of 2026-09-07 16:24 PDT, Allogene Therapeutics, Inc. (ALLO) trades at $1.97 on NasdaqGS. Its 52-week range is $1.04 to $3.06.
What is the market capitalisation of ALLO?
Allogene Therapeutics, Inc. (ALLO) has a market capitalisation of $679.95M on NasdaqGS.
What is the P/E ratio of ALLO?
ALLO trades at a trailing price-to-earnings (P/E) ratio of -2.56. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.76.
What is the return on equity (ROE) of ALLO?
ALLO has a return on equity (ROE) of -52.32%. Its return on capital employed (ROCE) is -53.97%.
Is ALLO a good stock to buy?
This page provides a data-driven analysis of Allogene Therapeutics, Inc. (ALLO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.